Avaden Biosciences, Inc. services

General Anatomic Pathology Services. Diagnostic reads for customer inventory or clinically derived samples. Specialty services – PD-L1 reads, special stains.

The basis of all Avaden sample queries is access to the EMR. Each Avaden clinical partner utilizes industry-leading EMR systems (Avaden requirement for partnership) . Facilitates sample identification, patient tracking / monitoring for multiple time point collections and multiple facilities. Establishes longitudinal history, treatment, and outcome data. Allows for linking of primary and metastatic resections. Self-populating over time.

Over 350 Clinical Data Points: Pathology (Dx), oncology (treatment), radiology (imaging), internal medicine (labs), other specialties.

Standard: Age, sex, diagnosis, stage (clinical), stage (TNM), grade, surgery date, molecular data.

Immediate access to over 35,000,000 unique accessions. Aggregation of surgical records from over 200 referring institutions. Direct access to patient Electronic Medical Records (EMRs). Over 350 data points per patient record. 10-15 years of history and outcome. All therapeutic areas.

Over 350 clinical data points per patient. Over 7,500 consented surgeries per month for custom tissue. Over 10,000 consented patients in ambulatory setting for blood draws. Fresh, FFPE, or frozen custom protocols - paired tissue/blood. 24 Hour guaranteed delivery to North America and Europe. Complete customization of patient inclusion / exclusion parameters. Single time point or patient tracking/monitoring.

Method comparison studies, interlaboratory reproducibility studies, enrollment studies, exploratory staining studies, digital pathology primary diagnosis , validations, new instrument validations.

Access to treatment and outcome from millions of patients. Electronic Medical Records from approximately 5% of US population.

More than 15,000 Referring Physicians. 5% of all US Surgeries in Avaden’s Network. Assay Development and Validation Studies. Reproducibility Studies. Enrollment Trials.

Each year, clinical facilities spend millions of dollars discarding human biospecimens after diagnostic processes have been completed.  Hospitals, clinics, and diagnostic labs unknowingly expend resources to incinerate hundreds of millions of valuable biological samples that could otherwise be re-purposed into critical R&D programs.  Avaden BioSciences provides clinics with an alternative.